Novo Nordisk A/S (NYSE:NVO) Shares Sold by Black Swift Group LLC

Black Swift Group LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 72.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 14,280 shares of the company’s stock after selling 37,720 shares during the quarter. Black Swift Group LLC’s holdings in Novo Nordisk A/S were worth $1,700,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of NVO. Advisor OS LLC raised its position in shares of Novo Nordisk A/S by 0.6% in the 2nd quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock worth $1,994,000 after buying an additional 82 shares during the period. Cascade Financial Partners LLC grew its holdings in shares of Novo Nordisk A/S by 2.3% during the 2nd quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock worth $543,000 after purchasing an additional 84 shares during the period. Novare Capital Management LLC raised its holdings in Novo Nordisk A/S by 3.2% in the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after buying an additional 85 shares during the period. AA Financial Advisors LLC increased its position in shares of Novo Nordisk A/S by 3.2% in the second quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock worth $400,000 after acquiring an additional 86 shares in the last quarter. Finally, Steel Grove Capital Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 2.3% during the 2nd quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after acquiring an additional 86 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $106.61 on Thursday. The firm has a market cap of $478.42 billion, a P/E ratio of 34.60, a P/E/G ratio of 1.29 and a beta of 0.42. The firm has a fifty day moving average of $119.68 and a two-hundred day moving average of $129.92. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15.

Analyst Ratings Changes

A number of research analysts have commented on the company. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.